- $317.77bn
- $361.24bn
- $65.01bn
Merck exec says company is discussing use of COVID antiviral drug in Ebola response
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Corrected: Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial (May 31)
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Live Markets: Eight trillion reasons UBS wants you to bet on longevity
Merck chicken bronchitis vaccine approved for use in China
Brief: Merck Co Inc Declares Q3 2026 Dividend Of $0.85 Per Share
Brief: Adcendo Aps Under Agreement, Co Will Sponsor Phase 1B Clinical Trial And Msd Will Provide Pembrolizumab
Factbox: Bundibugyo Ebola vaccines and treatments in development
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
Factbox: Bundibugyo Ebola vaccines and treatments in development
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers
Merck rises after co and partner Kelun's lung cancer combo meets late-stage trial goal
China's commerce ministry holds meeting with foreign pharmaceutical firms
U.S. STOCKS ON THE MOVE-NervGen Pharma, Medline, Silver miners
U.S. STOCKS ON THE MOVE-Estée Lauder, Perpetua Resources, Merck & Co
Brief: EMA's CHMP Recommends Extension To Marketing Authorisation For Wegovy
Merck rises after co and partner Kelun's lung cancer combo meets late-stage trial goal